ClinicalTrials.gg
CompletedNCT04437433JPN ATO OLEUpdated Jul 22, 2025Results posted

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

A Phase 3 interventional study of Atogepant 60 mg in Chronic Migraine and Episodic Migraine, sponsored by AbbVie. Completed at 24 sites in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
186
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
16th of 21
186 · median 468
Started
2020
the only one that year
Phase 3
15 of 21
3 open now
Registered
6th of 21
by date
Lead sponsor
11 of 21
AbbVie

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 16th largest by enrollment, is the only one that started in 2020, is one of 15 in phase 3, and was the 6th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).

Read the detailed description

The study recruited the following 2 cohorts:

3101-303-002 CM Completers: Japanese participants who completed lead-in Study 3101 303-002 (PROGRESS; NCT03855137), a Phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study of atogepant for the prevention of CM. All 3101 303-002 CM Completers rolled over at Visit 7 (the end of the double-blind treatment period) of the lead-in study, which functioned as Visit 1 for this study, Study 3101-306-002.

De Novo EM Participants: Japanese participants with EM who were newly recruited for this study at selected sites. Participation began with a 4-week Screening/Baseline period starting at Visit -1, and those who completed the 4-week Screening/Baseline period and met all entry criteria were enrolled into the 52-week open-label treatment period at Visit 1.

03

Conditions studied

  • Chronic Migraine
  • Episodic Migraine

Browse trials for

Keywords

  • Chronic Migraine
  • Episodic Migraine
  • Atogepant
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

3101-303-002 Completers:

  • Eligible participants who completed Visit 7, and Visit 8 if applicable, of the Study 3101-303-002 without significant protocol deviations and who did not experience an adverse event (AE) that, in the investigator's opinion, may indicate an unacceptable safety risk.

De Novo EM Participants:

  • Age of the participant at the time of migraine onset \< 50 years.
  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3, 2018.
  • History of 4 to 14 migraine days per month on average in the 3 months prior to Visit -1 in the investigator's judgment.
  • 4 to 14 migraine days in the 28-day baseline period per eDiary.
  • Completed at least 20 out of 28 days in the eDiary during baseline period and is able to read, understand, and complete the study questionnaires and eDiary per investigator's judgment.

Exclusion criteria

Exclusion Criteria:

  • Requirement for any medication, diet, or nonpharmacological treatment that is on the list of prohibited concomitant medications or treatments that cannot be discontinued or switched to an allowable alternative medication or treatment.
  • Participants with an indicating abnormalities at Visit -1 (De Novo EM Participants) or Visit 1 (3103-303-002 Completers).
  • Hypertension as defined by sitting systolic BP > 160 mm Hg or sitting diastolic BP > 100 mm Hg at Visit -1 (De Novo EM Participants) or Visit 1 (for all participants)
  • Significant risk of self-harm based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator.
  • Any clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

De Novo EM Participants only:

  • Difficulty distinguishing migraine headaches from tension-type or other headaches.
  • Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018.
  • Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018.
  • Has >= 15 headache days per month on average across the 3 months prior to Visit -1 in the investigator's judgment.
  • Has >= 15 headache days in the 28-day baseline period per eDiary.
  • Usage of opioids or barbiturates > 2 days/month, triptans or ergots >= 10 days/month, or simple analgesics >= 15 days/month in the 3 months prior to Visit -1 per investigator's judgment or during the baseline period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    Atogepant 60 mg Chronic Migraine

    Participants with chronic migraine (CM) who completed lead-in Study 3101-303-002 (NCT03855137) received atogepant orally as 60 mg tablets once a day (QD) for 52 weeks.

    Drug: Atogepant 60 mg

  • Experimental
    Atogepant 60 mg Episodic Migraine

    Participants with episodic migraine (EM) who were newly recruited and met all study entry criteria received atogepant orally as 60 mg tablets once a day (QD) for 52 weeks.

    Drug: Atogepant 60 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)

Secondary outcomes

  1. Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator

    Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis.

    Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)

  2. Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

    12-lead ECGs were performed at select study visits.

    Time frame: Week -4 (De Novo Participants), Day 1 (3101-303-002 Completers Only), Weeks 12, 24, 36, and 52

  3. Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

    Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], and weight.

    Time frame: From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)

  4. Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

    Time frame: From first dose of study drug until the last dose of study drug (up to 52 weeks)

  5. Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Safety Follow-Up Period

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

    Time frame: Up to 4 weeks following the last dose of study drug

07

Results

Posted Jul 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
Started15531
Completed13028
Not completed253
Withdrew: Met withdrawal criteria at visit 1- laboratory values70
Withdrew: Met withdrawal criteria at visit 1- ecg10
Withdrew: Adverse event90
Withdrew: Lack of efficacy40
Withdrew: Withdrawal by subject41
Withdrew: Protocol deviation01
Withdrew: Other, not specified01

Outcome measures

PrimaryPercentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
Any TEAE88.490.3
TESAE4.50.0
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator

Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. The percentage of participants with PCS laboratory values are summarized for hematology, chemistry, and urinalysis.

Time frame:
From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values (Chemistry, Hematology, Urinalysis) as Assessed by the Investigator
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
Basophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0.00.0
Eosinophils (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0.00.0
Erythrocytes, Hematology (10^12/L): < 0.9 x Lower Limit of Normal (LLN)3.23.2
Erythrocytes, Hematology (10^12/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Hematocrit (RATIO): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Hematocrit (RATIO): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Hemoglobin (g/L): < 0.9 x Lower Limit of Normal (LLN)3.30.0
Hemoglobin (g/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Leukocytes, Hematology (10^9/L): < 0.9 x Lower Limit of Normal (LLN)12.817.2
Leukocytes, Hematology (10^9/L): > 1.5 x Upper Limit of Normal (ULN)0.00.0
Lymphocytes (10^9/L): < 0.7 x Lower Limit of Normal (LLN)1.90.0
Lymphocytes (10^9/L): > 1.3 x Upper Limit of Normal (ULN)0.00.0
Monocytes (10^9/L): < 0.5 x Lower Limit of Normal (LLN)0.00.0
Monocytes (10^9/L): > 2.0 x Upper Limit of Normal (ULN)0.00.0
Neutrophils (10^9/L): < 0.7 x Lower Limit of Normal (LLN)2.63.2
Neutrophils (10^9/L): > 1.3 x Upper Limit of Normal (ULN)0.70.0
Platelets (10^9/L): < 0.5 x Lower Limit of Normal (LLN)0.00.0
Platelets (10^9/L): > 1.5 x Upper Limit of Normal (ULN)1.30.0
Alanine Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)5.80.0
Albumin (g/L): < 0.8 x Lower Limit of Normal (LLN)0.00.0
Albumin (g/L): > 1.2 x Upper Limit of Normal (ULN)0.00.0
Alkaline Phosphatase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)0.60.0
Aspartate Aminotransferase (U/L): ≥ 3.0 x Upper Limit of Normal (ULN)3.20.0
Bicarbonate (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.63.2
Bicarbonate (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Bilirubin, Chemistry (umol/L): ≥ 1.5 x Upper Limit of Normal (ULN)0.60.0
Calcium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Calcium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Chloride (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Chloride (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Cholesterol (mmol/L): > 1.6 x Upper Limit of Normal (ULN)0.00.0
Creatine Kinase (U/L): > 2.0 x Upper Limit of Normal (ULN)2.60.0
Creatinine (umol/L): > 1.5 x Upper Limit of Normal (ULN)0.00.0
Glomerular Filtration Rate, Estimated (mL/min/1.73): < 60 mL/min/1.73m^21.93.3
Glucose, Chemistry (mmol/L): < 0.8 x Lower Limit of Normal (LLN)1.90.0
Glucose, Chemistry (mmol/L): > 2.0 x Upper Limit of Normal (ULN)0.00.0
Lactate Dehydrogenase (U/L): > 3.0 x Upper Limit of Normal (ULN)0.60.0
Phosphate (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Phosphate (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Potassium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Potassium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Protein, Chemistry (g/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Protein, Chemistry (g/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Sodium (mmol/L): < 0.9 x Lower Limit of Normal (LLN)0.00.0
Sodium (mmol/L): > 1.1 x Upper Limit of Normal (ULN)0.00.0
Urate (umol/L): > 1.2 x Upper Limit of Normal (ULN)0.00.0
Urea Nitrogen (mmol/L): > 1.5 x Upper Limit of Normal (ULN)0.00.0
Glucose, Urinalysis: At least 1+1.30.0
Protein, Urinalysis: At least 1+28.726.7
Specific Gravity: > 1.1 x Upper Limit of Normal (ULN)0.00.0
pH: < 0.9 x Lower Limit of Normal (LLN)0.00.0
pH: > 1.1 x Upper Limit of Normal (ULN)0.00.0
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator

12-lead ECGs were performed at select study visits.

Time frame:
Week -4 (De Novo Participants), Day 1 (3101-303-002 Completers Only), Weeks 12, 24, 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
PR Interval (msec): ≥ 2500.00.0
QRS Duration (msec): ≥ 1500.00.0
QTcF Interval (msec): > 5000.00.0
QTcF Interval (msec): Increase from Baseline of > 600.00.0
SecondaryPercentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator

Potentially Clinically Significant post-Baseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], and weight.

Time frame:
From first dose of study drug until 4 weeks following the last dose of study drug (up to 56 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
Sitting, Standing Systolic Blood Pressure (mmHg): ≥ 180 and increase from Baseline of ≥ 200.00.0
Sitting, Standing Systolic Blood Pressure (mmHg): ≤ 90 and decrease from Baseline of ≥ 205.89.7
Sitting, Standing Diastolic Blood Pressure (mmHg): ≥ 105 and increase from Baseline of ≥ 154.53.2
Sitting, Standing Diastolic Blood Pressure (mmHg): ≤ 50 and decrease from Baseline of ≥ 150.60.0
Sitting, Standing Pulse Rate (bpm): ≥ 120 and increase from Baseline of ≥ 150.60.0
Sitting, Standing Pulse Rate (bpm): ≤ 50 and decrease from baseline of ≥ 151.30.0
Weight (kg): Increase from Baseline of ≥ 7%4.53.2
Weight (kg): Decrease from Baseline of ≥ 7%32.925.8
Orthostatic Systolic Blood Pressure (mmHg): ≤ -2012.46.5
Orthostatic Diastolic Blood Pressure (mmHg): ≤ -153.90.0
Orthostatic Pulse Rate (bpm): ≥ 254.56.5
SecondaryPercentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

Time frame:
From first dose of study drug until the last dose of study drug (up to 52 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Open-Label Treatment Period
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
No suicidal ideation98.1100
Suicidal ideation1.30.0
Most severe suicidal ideation: Active suicidal ideation with specific plan and intent0.00.0
Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan0.00.0
Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act0.00.0
Most severe suicidal ideation: Non-specific active suicidal thoughts0.60.0
Most severe suicidal ideation: Wish to be dead0.60.0
No suicidal behavior100100.0
Suicidal behavior0.00.0
Most severe suicidal behavior: Actual attempt0.00.0
Most severe suicidal behavior: Interrupted attempt0.00.0
Most severe suicidal behavior: Aborted attempt0.00.0
Most severe suicidal behavior: Preparatory acts or behavior0.00.0
Completed Suicide0.00.0
Non-suicidal self-injurious behavior0.00.0
SecondaryPercentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Safety Follow-Up Period

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior).

Time frame:
Up to 4 weeks following the last dose of study drug
Reported as:
Number · percentage of participants
Percentage of Participants With Most Severe Suicidal Ideation and Suicidal Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) During the Safety Follow-Up Period
percentage of participantsAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic Migraine
No suicidal ideation10093.5
Suicidal ideation0.00.0
Most severe suicidal ideation: Active suicidal ideation with specific plan and intent0.00.0
Most severe suicidal ideation: Active suicidal ideation with some intent to act, w/out specific plan0.00.0
Most severe suicidal ideation: Active suicidal ideation w/ any method (not plan) w/out intent to act0.00.0
Most severe suicidal ideation: Non-specific active suicidal thoughts0.00.0
Most severe suicidal ideation: Wish to be dead0.00.0
No suicidal behavior10093.5
Suicidal behavior0.00.0
Most severe suicidal behavior: Actual attempt0.00.0
Most severe suicidal behavior: Interrupted attempt0.00.0
Most severe suicidal behavior: Aborted attempt0.00.0
Most severe suicidal behavior: Preparatory acts or behavior0.00.0
Completed Suicide0.00.0
Non-suicidal self-injurious behavior0.00.0

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 392 days for the Atogepant 60 mg Chronic Migraine group, 421 days for the Atogepant 60 mg Episodic Migraine group, and 392 days for all participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atogepant 60 mg Chronic Migraine0/155 (0%)7/155 (4.5%)108/155 (69.7%)
Atogepant 60 mg Episodic Migraine0/31 (0%)0/31 (0%)24/31 (77.4%)
Total0/186 (0%)7/186 (3.8%)132/186 (71%)
Most frequent serious events
Most frequent serious events
EventAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
VERTIGOEar and labyrinth disorders1/1550/311/186
CHOLELITHIASISHepatobiliary disorders1/1550/311/186
APPENDICITISInfections and infestations1/1550/311/186
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/1550/311/186
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/1550/311/186
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1550/311/186
LOSS OF CONSCIOUSNESSNervous system disorders1/1550/311/186
MIGRAINENervous system disorders1/1550/311/186
DEPRESSIONPsychiatric disorders1/1550/311/186
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAtogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
NASOPHARYNGITISInfections and infestations18/15512/3130/186
PYREXIAGeneral disorders52/1552/3154/186
COVID-19Infections and infestations1/1556/317/186
CONSTIPATIONGastrointestinal disorders17/1554/3121/186
ALANINE AMINOTRANSFERASE INCREASEDInvestigations10/1553/3113/186
CYSTITISInfections and infestations11/1551/3112/186
DRY EYEEye disorders4/1552/316/186
ABDOMINAL PAIN UPPERGastrointestinal disorders6/1552/318/186
DIARRHOEAGastrointestinal disorders8/1552/3110/186
STOMATITISGastrointestinal disorders3/1552/315/186

Baseline characteristics

Safety population: all participants who received at least 1 dose of study intervention (atogepant) in this extension study

Age, Continuous
Age, Continuous(years)Atogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
Mean43.4 ± 9.4742.4 ± 11.9543.2 ± 9.90
Sex: Female, Male
Sex: Female, Male(Participants)Atogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
Female14129170
Male14216
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Atogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
Hispanic or Latino000
Not Hispanic or Latino15531186
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Atogepant 60 mg Chronic MigraineAtogepant 60 mg Episodic MigraineTotal
American Indian or Alaska Native000
Asian15531186
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

24 sites
  • Takanoko Hospital /ID# 232723
    Matsuyama, Ehime 790-0925, Japan
  • Fukuiken Saiseikai Hospital /ID# 232988
    Fukui-shi, Fukui 918-8503, Japan
  • Duplicate_Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 232710
    Sapporo, Hokkaido 003-0003, Japan
  • Konan Medical Center /ID# 232922
    Kobe, Hyōgo 658-0064, Japan
  • Mito Kyodo General Hospital /ID# 232990
    Mito, Ibaraki 310-0015, Japan
  • Atsuchi Neurosurgical Hospital /ID# 232907
    Kagoshima, Kagoshima-ken 892-0842, Japan
  • Duplicate_Tokai University Hospital /ID# 233071
    Isehara-shi, Kanagawa 259-1193, Japan
  • Fujitsu Clinic /ID# 232717
    Kawasaki-shi, Kanagawa 211-8588, Japan
  • Umenotsuji Clinic /ID# 232675
    Kochi, Kochi 780-8011, Japan
  • Sendai Headache and Neurology Clinic Medical Corporation /ID# 232677
    Sendai, Miyagi 982-0014, Japan
  • Saitama Medical University Hospital /ID# 233017
    Iruma-gun, Saitama 350-0495, Japan
  • Saitama Neuropsychiatric Institute /Id# 232711
    Saitama-shi, Saitama 338-8577, Japan
  • Japanese Red Cross Shizuoka Hospital /ID# 232992
    Shizuoka, Shizuoka 420-0853, Japan
  • Duplicate_Dokkyo Medical University Hospital /ID# 232995
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • Niwa Family Clinic /ID# 232713
    Chofu-shi, Tokyo 182-0006, Japan
  • Duplicate_Tokyo Headache Clinic /ID# 232715
    Shibuya-ku, Tokyo 151-0051, Japan
  • Keio University Hospital /ID# 233030
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Duplicate_Nagaseki Headache Clinic /ID# 232719
    Kai-shi, Yamanashi 400-0124, Japan
  • DOI Internal Medicine-Neurology Clinic /ID# 232722
    Hiroshima, 730-0031, Japan
  • Hiroshima Neurology Clinic /ID# 232720
    Hiroshima, 732-0822, Japan
  • Tanaka Neurosurgical Clinic /ID# 232884
    Kagoshima, 892-0844, Japan
  • Tatsuoka Neurology Clinic /ID# 232912
    Kyoto, 600-8811, Japan
  • Tominaga Hospital /ID# 232909
    Osaka, 556-0017, Japan
  • Shinagawa Strings Clinic /ID# 232908
    Tokyo, 108-0075, Japan
09

References and documents

Publications

  • Matsumori Y, Nagy K, Takahashi A, Tanaka S, Takeshima T, Forero G, Bao J, Guo H, Ahmadyar G, de Abreu Ferreira R, Yamamoto T. Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study. Neurol Ther. 2026 Jun;15(3):1137-1154. doi: 10.1007/s40120-026-00905-3. Epub 2026 Mar 11. PubMed 41814051 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jun 2024, 47 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 47 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 18, 2020
StartActual
Jun 18, 2020
Primary completionActual
Jun 11, 2024
CompletionActual
Jun 11, 2024
Results first posted
Jul 22, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04437433
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Jun 18, 2020
Primary completion
Jun 11, 2024
Completion
Jun 11, 2024
Results posted
Jul 22, 2025
Last update
Jul 22, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion